The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 465-471

  Giroux Leprieur, Etienne ^a,b,c   Hirata, Tomomi ^a,d   Mo, Minli ^e   Chen, Zhao ^a   Okamoto, Junichi ^a,d   Clement, Genevieve ^a   Li, Hui ^a   Wislez, Marie ^b   Jablons, David M ^a,f   He, Biao ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e TSINGHUA UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EMX2; Mesothelioma; Neoadjuvant chemotherapy; Overall survival; Predictive marker; Prognosis; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; TRANSCRIPTION FACTOR EMX2; BIOLOGICAL MARKER; EMPTY SPIRACLES HOMEOBOX PROTEINS; HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DOWN REGULATION; ETHNICITY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; TUMOR VOLUME; DISEASE COURSE; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURAL NEOPLASMS; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84926406746     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.018     Document Type: Article

References (26)

1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
2. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant pleural mesothelioma. J Clin Oncol 2009, 27:2081-2090.
3. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995, 108:1122-1128.
4. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., Morrow M. AJCC Cancer Staging Manual 2002, Springer, New York. 6th edition.
5. Sobin L.H., Wittekind C. International Union Against Cancer (UICC): TNM classification of malignant tumours 2002, Wiley-Liss, New York.
6. Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L, et al.Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 2010, 116:1510-1517.
7. Bueno R. Making the case for molecular staging of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009, 21:188-193.
8. Dalton D., Chadwick R., McGinnis W. Expression and embryonic function of empty spiracles: a Drosophila homeo box gene with two patterning functions on the anterior-posterior axis of the embryo. Genes Dev 1989, 3:1940-1956.
9. Galli R, Fiocco R, De Filippis L, Muzio L, Gritti A, Mercurio S, et al.Emx2 regulates the proliferation of stem cells of the adult mammalian central nervous system. Development 2002, 129:1633-1644.
10. Ligon KL, Echelard Y, Assimacopoulos S, Danielian PS, Kaing S, Grove EA, et al.Loss of Emx2 function leads to ectopic expression of Wnt1 in the developing telencephalon and cortical dysplasia. Development 2003, 130:2275-2287.
11. Taylor H.S., Fei X. Emx2 regulates mammalian reproduction by altering endometrial cell proliferation. Mol Endocrinol 2005, 19:2839-2846.
12. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, et al., EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene 2010, 29:5969-5975.
13. Noonan F.C., Mutch D.G., Ann Mallon M., Goodfellow P.J. Characterization of the homeodomain gene EMX2: sequence conservation, expression analysis, and a search for mutations in endometrial cancers. Genomics 2001, 76:37-44.
14. Lind G.E., Skotheim R.I., Fraga M.F., Abeler V.M., Esteller M., Lothe R.A. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J Pathol 2006, 210:441-449.
15. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, et al., A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008, 14:5565-5570.
16. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
17. Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly. Nat Genet 1996, 12:94-96.
18. Cecchi C. Emx2: a gene responsible for cortical development, regionalization and area specification. Gene 2002, 291:1-9.
19. Boersma C.J., Bloemen M., Hendriks J.M., van Berkel E.A., Olijve W., van Zoelen E.J. Homeobox proteins as signal transduction intermediates in regulation of NCAM expression by recombinant human bone morphogenetic protein-2 in osteoblast-like cells. Mol Cell Biol Res Commun 1999, 1:117-124.
20. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence. Nat Rev Cancer 2002, 2:777-785.
21. Flores R.M. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 2005, 49(Suppl. 1):S71-S74.
22. Tsao A.S., Mehran R., Roth J.A. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 2009, 10:36-41.
23. Weder W., Kestenholz P., Taverna C., Bodis S., Lardinois D., Jerman M., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451-3457.
24. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al., Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27:3007-3013.
25. Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, et al., Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005, 23:184-189.
26. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.